Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mymd Pharmaceuticals Inc (NQ: MYMD )

1.720 +0.020 (+1.18%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 31, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 567,248
Open 1.730
Bid (Size) 1.610 (2)
Ask (Size) 1.850 (11)
Prev. Close 1.700
Today's Range 1.675 - 1.750
52wk Range 0.9000 - 6.150
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
From MyMD Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga

Performance

YTD
+47.01%
+47.01%
1 Month
-9.95%
-9.95%
3 Month
+49.57%
+49.57%
6 Month
-32.28%
-32.28%
1 Year
-61.17%
-61.17%

More News

Read More
MyMD Joins LOT Network To Protect Company And Shareholders From Patent Trolls
Via Benzinga
MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls
From MyMD Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
DEA Concludes MyMD's Supera-CBD Is Not A Controlled Substance Or Listed Chemical
Via Benzinga
MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD™ is not a Controlled Substance or Listed Chemical
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF-α Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Announces $15 Million Offering with Existing Investors
From MyMD Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Why Top Ships Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Why Heart Test Laboratories Are Trading Higher By 136%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022
From MyMD Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress
From MyMD Pharmaceuticals, Inc.
Via Business Wire
MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Why Oil-Related Stocks Traded Higher; Here Are 74 Biggest Movers From Yesterday
Via Benzinga
Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday
Via Benzinga
Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
From MyMD Pharmaceuticals, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.